Clinical studies of new anti-tubercular drugs are costly and time consuming. Owing 31 to the extensive TB treatment periods, the ability to identify drug candidates based on 32 their predicted clinical efficacy is vital to accelerate the pipeline of new therapies. 33
). Our results concur with several clinical studies, as displayed in 176 Table S2 and Figure 4 . PDi based odds ratios were estimated to be 1.726 (CI: 1.216-177 2.45) which compares with reported or calculated ratios from clinical literature data 178 (Table S2 , Fig. 4 ). PDi prediction of culture conversion rates for MXF containing 179 regimens seems to be marginally faster than that observed in the most comprehensive 180 study (11). However, our prediction is in line with the median of 8 different clinical 181 studies over 8 weeks ( Fig. 4b and Table S2 ). 182 183 Table S3 displays the sensitivity analysis of the PDi modelling (see Methods), which 184 indicates that the maximal kill rate (E max ) of MXF is the most influential parameter 185 upon bacillary clearance. The second most significant parameter is the initial 186 intracellular burden the patient presents at the clinic, concurring with previous clinical 187 studies (28, 29) , followed by the PK parameters and MXF drug potency (EC 50 ). 188
Potency and PK parameters of RIF ranked lower than MXF parameters in our (Table S4 ). Simulations predict MXF to have superior PK properties due to 201 its relatively high AUC level in the plasma, and it displays the highest accumulation 202 in the ELF. Table S4 shows that LVX at a higher dose of 750 mg/day would achieve 203 a very similar pulmonary PK profile to that observed for MXF at 400 mg/day. 204
Assuming linear PK for LVX, 500 mg/day is expected to achieve inferior ELF 205 exposure to 400 mg/day of MXF. At 1000 mg dose, LVX has a comparable ELF 206 AUC value (221.7 mg.h/L) compared to a standard dose of MXF of 400 mg/day 207 (173.1 mg.h/L). Systematic PK parameters were chosen from previously reported 208 data as per Table S4 . 209
210
Simulating various doses of LVX and MXF and integrating this with our imaging-211 based PDi data, reveals that an increase of LVX from 500 mg to 1000 mg results in a 212 remarkable improvement in activity (88% of patients predicted to achieve negative 213 culture conversion at 8 weeks with 500 mg LVX Vs. 93% of patients predicted to 214 achieve negative culture conversion at 8 weeks with 1000 mg LVX, Fig. 5 ). In 215 contrast, we predict that an increase in the dose of MXF from 400 mg to 800 mg 216 would result in a more modest improvement (95% of patients to achieve culture 217 negative status with 400 mg MXF Vs. 96% with MXF 800 mg) ( Fig. 5 ). 218
219
Using PDi -based modelling to predict TB treatment duration and risk of relapse 220 221 As described, fluoroquinolones have been clinically assessed in efforts to shorten 222 standard therapy (7, 20, 30). We believe culture conversion is related to relapse rates 223 and hypothesise that following culture conversion, further therapy is required to kill 224 hidden/recalcitrant bacilli populations. Figure 6 displays how many patients would 225 hypothetically be at risk of disease relapse when comparing the standard regimen to a 226 MXF arm for 4 or 5-months. We hypothesise that this is directly related to the time 227 taken to culture convert during treatment, which will differ between all patients. As 228 on October 23, 2019 at LIVERPOOL SCH OF TROPICAL MED http://aac.asm.org/ Downloaded from 8 shown, 6% of patients in the standard treatment arm will culture convert late (<80 229 days before end of treatment), and therefore not receive treatment for 80 days post 230 conversion, compared to 15% in the 4-month MXF and 4% in the 5-month MXF arm. 231
Discussion

233
PDi modelling has previously been utilised for the prediction of treatment outcome 234 for TB patients receiving standard or high dose RIF therapy (22, 31) Herein, we have 235 used a similar approach to predict treatment outcomes using fluoroquinolone-based 236 regimens. Fluoroquinolones have been considered by many to be a means of 237 shortening the current standard therapy (7, 20, 30). 238
239
We have presented intracellular killing kinetics for 6 different fluoroquinolone drugs 240 assessed using two methods. The first method is useful for rapid ranking of the 241 potency of the various drugs resulting in concentration-effect relationships (Table S1) . 242
This allows for the identification of the best candidates for further analysis. The 243 results demonstrated that 4 out of the 6 fluoroquinolones have similar potencies 244 (MXF, LVX, CIP, SPX). Despite RIF, our control compound, being superior overall, 245 MXF displayed a similar maximal kill rate in both the live fluorimetry and the fixed 246 Operetta assay. Yet, patients treated with a 4-month regimen containing MXF 247 showed higher rates of disease relapse despite achieving faster culture conversion in 248 comparison to standard treatments (11). MXF however, has superior PK properties 249 compared to a standard regimen of RIF (which is currently dosed sub-optimally), 250 especially in its accumulation in the lung and ELF. The high accumulation levels 251 compensate for the lower potency when compared to RIF and leads to better overall 252 effect in Monte Carlo simulations, predicting a median culture conversion time of 31 253 days compared to 56 days for standard treatment. 254 255 Our intracellular data was in agreement with data from a murine macrophage study, 256
showing that NOX and OXF are significantly less potent than MXF (32). Whilst SPX 257 displayed the lowest EC 50 , cytotoxicity was observed as reported in the literature (33) 258 therefore it was eliminated from further investigation. MXF, CIP and LVX showed 259 similar potency and maximal kill rates. CIP displayed a similar EC 50 to MXF in our 260 study but at 500 mg it has 10-fold lower exposure in the ELF when compared to MXF 261 on October 23, 2019 at LIVERPOOL SCH OF TROPICAL MED http://aac.asm.org/ Downloaded from 9 at 400 mg (25). Therefore, only MXF and LVX were considered further in our 262 analyses. A 1000 mg dose of LVX has a comparable ELF AUC value (221.7 mg.h/L) 263 compared to a standard dose of MXF of 400 mg/day (173.1 mg.h/L, Table S4 ) and 264 that at this higher dose, the clinical efficacy of LVX, in terms of culture conversion 265 rates, is predicted by the PDi-based modelling to be comparable to MXF (Fig. 5) . 266
This observation is consistent with a recent clinical study comparing MXF (400 mg) 267 to high dose (750 mg) LVX, demonstrating that both regimens results in a similar 268 clinical outcome (34, 35) . These data support that, in the absence of any safety 269 concerns, LVX should be further trialed at higher doses. 270 271 Similar to the work described previously (22), we show that it is the intracellular kill 272 rate of MXF that limits the reduction of CFU burden, even when the intracellular 273 population represents just 5% of the overall population (with in our model 95% 274
represented by extracellular Mtb). Supplementary figure 4 displays the biexponential 275 nature of CFU reduction which, in our simulation, is a direct result of having two 276 separate populations (extracellular and intracellular) ( Fig. S4 ). 277
278
That our PDi-based modelling approach (using short-term measurements of 279 intracellular Mtb killing) is able to predict long-term clinical responses, is perhaps not 280 surprising when it is considered that the majority of patients (ca. 80 %) culture 281 convert within ca. 8 weeks of treatment (36) . We have previously shown that clinical 282 biphasic treatment responses can be explained by an initial reduction in extracellular 283
Mtb followed by a second slower phase of bacillary clearance that largely corresponds 284 to the killing dynamics of intracellular (macrophage) Mtb (22, 37). The duration of 285 this second slower bacillary clearance rate is typically 5-6 weeks. Therefore, the PDi-286 based modelling approach should be viewed as a predictive tool to determine the 287 clinical response over this shorter time-frame, which is nonetheless a critical clinical 288 feature to assess drug efficacy. Clearly, the PDi-based modelling approach does not 289 take into account the response to treatment of slow growing/dormant bacilli, which 290 are thought to be relevant to TB treatment outcome (38). However, given the strong 291 agreement in the PDi-based modelling to observed clinical bacillary clearance 292 responses, it is our view that these important PD and PK considerations are more 293 relevant in terms of predicting microbiological treatment outcomes and potentially 294 treatment relapse rates. As described, this study proposes that a useful proxy to 295 on October 23, 2019 at LIVERPOOL SCH OF TROPICAL MED http://aac.asm.org/ Downloaded from estimating disease relapse is the treatment duration post culture conversion, and 296 therefore knowledge of bacillary clearance rates for drugs and drug combinations can 297 be used to inform treatment outcome and relapse rates. 298
Should MXF be introduced to the standard treatment? 299 300 Incorporating MXF into treatment regimens results in faster clearance rates of bacilli 301 compared to standard treatment in 8 different clinical studies (39).
As 302 aforementioned, Gillespie et al. 2014 showed that a 4-month MXF based treatment 303 results in a higher relapse rate (11, 21). Superior culture conversion results indicate 304 that relapse rates should be lower in the MXF arm. PDi simulations can accurately 305 predict the percentage of patients reaching culture-negative status when compared to 306 observed clinical findings (Table S2 ). Additionally, sensitivity analysis (Table S3 ) 307
indicates that MXF in these regimens is the main driver of activity in combination 308 treatments and its effect significantly supersedes that of RIF, thus explaining the 309 accelerated clearance of bacilli when MXF is introduced to the drug regimen. 310 311 However, the culture conversion rates in clinical findings did not predict the high 312 relapse rate in the MXF arm that was reported in Gillespie et al. 2014 . One 313 explanation of this disparity between bacilli clearance rates and disease relapse could 314 be related to length of time treatment is received after achieving negative culture 315 conversion. This will vary between individual patients. We hypothesise that each 316 patient requires treatment exceeding 80-days following culture conversion. For 317 example, according to our PDi predictions, in the 4-month MXF arm 12% -17% of 318 patients will be at risk of relapse as they will culture convert late and receive 319 treatment for less than 80-days after culture converting (Fig. 6 ). In contrast, only 7% 320 will be at risk of relapse in the standard 6-month arm. The remaining 93% will 321 remain on treatment for more than 80-days after culture conversion. We have 322 suggested an 80-day duration post culture conversion, because this is the duration that 323 predicts 15% relapse rate which agrees with relapse rates observed in the Gillespie et whereas parameters for fluoroquinolone drugs were derived from experiments 453 described herein. Supplementary Table 5 summarises the parameters used for the 454 simulation with the corresponding references. 455
456
We observed a very strong correlation between the growth rate and the corresponding 457 kill rate in all experiments for all drugs screened. RIF and MXF exhibited similar 458 maximal kill rates that always varied between 1.6-2-fold higher than the growth rate, 459 regardless if the latter was fast or slow. The consistency in the ratio between the 460 growth and kill rates allows the ability to correct all data to a fixed growth rate, in all 461 simulations, to reduce output noise whilst not compromising the final outcomes. 462
Reported intracellular Mtb growth rates (also known as doubling times, DT), 463 15 including those reported by us, range from DT 21 h to DT 48 h, (22, 44, 45) whilst in 464 vivo rodent TB models report an intracellular DT for Mtb close to 25 h (46). The 465 reason for the reported variation is not fully understood, but could be partially 466 explained by macrophage modulation of M0/M1/M2 polarisation (37). For the 467 described PDi-based modelling approach, we chose a DT of 21 h for consistency with 468 previous studies and to avoid bias in cross-study comparisons in the future. 469 470 471
Monte Carlo Simulations 472 473
Monte Carlo simulations for PK/PD predictions were performed using Pmetrics ® with 474 PK parameters derived from the literature. PK values for MXF were chosen from 475 studies where MXF was administered with RIF, due to the known PK interaction 476 between the two drugs (23, 24). PK for other standard drugs were used as previously 477 described (22). 478
479
The models utilised for Monte Carlo simulations herein were previously described in 480 detail in (22, 31). Briefly, the CFU reduction in each simulated patient was driven by 481 exposure to drug and kill rate of each drug according to an Emax model (Eq. 3). 482
Extracellular and intracellular bacilli respond differently to drug treatment and both 483 reservoirs were simultaneously simulated for each patient, resulting in a biexponential 484 decrease in total CFU burden over time (Fig. S3 ). Overall drug kill rate (of all drugs 485 in combination) is equal to the rate of the fastest acting drug at the same time. This is 486 determined by the epithelial lining fluid (ELF) drug exposure and its intrinsic rate of 487 kill (as defined in vitro) at any given time point for each drug. assumed that a 10 CFU/mL or lower outcome at any given time would indicate 499 culture conversion to be negative, as previously described (22). The number of 500 patients converting to culture negative status in the simulation every week was then 501 recorded for further survival analysis. Supplementary Table 5 summarises the 502 parameters used for the simulation with the corresponding references. 503 504 Odds ratios were calculated using IBM ® SPSS ® Statistics Version 24 (property of 505 IBM Corp). Data generated form Monte Carlo simulation from different scenarios 506 were compared head to head and the odds ratio with 95CI was estimated accordingly. 507 508 Sensitivity analysis was performed to assess the most influential parameters upon the 509 bacillary clearance within the simulation (Table S3 ). The analyses were performed 510 using the FME package (A Flexible Modelling Environment for Inverse Modelling, 511
Sensitivity, Identifiability and Monte Carlo Analysis) with R version 3.4.2 (48). 512
Influence of each parameter was expressed in terms of L1-norm and L2-norm 513 measures which rank parameters by their effect upon the simulation. The higher the 514 L1-norm or L2-norm for a given parameter, the higher the sensitivity (49). Sensitivity 515
analysis (Table S3) shows that MXF would be the main driver of activity in a 516 combination of drugs. This is further corroborated by observing the changing kill rate 517 over time for each of the partner drugs which shows that MXF dominates as the 518 fastest killer throughout the treatment duration, followed by RIF while INH and PZA 519 play a negligible role in the overall clearance of bacilli (Fig. S5) . 520 521 522
Methodological assumptions and limitations 523 524
Whilst fluorimetric-based measurements of intracellular Mtb can effectively measure 525 bacillary growth, this approach has a limited dynamic range when assessing bacillary 526 sterilisation over time when measurements fall below the minimum limit of 527 fluorescence detection. To overcome this issue, high-content (Operetta) imaging was 528 used to more accurately measure time-dependent bacillary sterilisation for specific 529 drugs. With regards to intracellular Mtb growth, during the course of this and our 530 other studies, as well as in studies by other laboratories, we noted a variation in 531 on October 23, 2019 at LIVERPOOL SCH OF TROPICAL MED http://aac.asm.org/ Downloaded from intracellular Mtb DT, as aforementioned in the 'Modelling Parameters' section. To 532 normalise for this in our mathematical modelling, we selected a DT of 21 h 533 throughout. Furthermore, for the purpose of the mathematical modelling/simulations 534 to predict clinical outcome, in the absence of evidence to the contrary, we also made a 535 number of assumptions, including; (i) it was assumed that there is no pharmacological 536 interaction [synergy/additivity/antagonism] between the modelled drugs, therefore the 537 clinically observed Mtb sterilisation rate was equivalent to the sterilisation rate of the 538 drug with the fastest sterilisation rate. It was also hypothesised that (ii) PD 539 interactions of drugs against intracellular (macrophage) Mtb measured in in vitro 540 culture were similar to those in the ELF. 541
542
It should be noted that whilst time-dependent intracellular Mtb sterilisation rates and 543
PDi -PK modelling have been used in this study to predict the clinical activity of 544 fluoroquinolones against TB, this approach generates dynamic parameters (e.g. 
